Feasibility Aspects of Exploring Exercise-Induced Neuroplasticity in Parkinson’s Disease: A Pilot Randomized Controlled Trial

Table 3

Demographic and clinical characteristics of the participants at baseline.

Characteristics; Median (min–max) unless otherwise stated	HiBalance (n = 7)	Control (n = 6)
Age, y	72.0 (60–78)	67.5 (63–70)
Sex, n female	1	3
LEDD (mg)^1	700 (380–920)	765.5 (525–1171)
Body mass index, kg/m^2	23.5 (19.6–25.9)	24.4 (21.2–26.8)
Years with PD	10.0 (3–13)	7.0 (3–11)
Hoehn and Yahr^2, 0–5	2	2.5
2, n	5	3
3, n	2	3
MDS-UPDRS part III, 0–132^3	35.0 (24–46)	32.5 (22–52)
Falls in last year, n	0 (0–4)	0 (0–3)
Mini-BESTest, 0–28^4	24.0 (21–27)	22.5 (19–25)
Montreal Cognitive Assessment^5	27.0 (26–30)	26.5 (21–28)

¹Levodopa daily equivalent dosage. ²Stages of disease progression from 1 to 5 (1 = minimal disability; 5 = confined to bed/wheelchair). ³Movevement disorder society-unified Parkinson’s disease rating scale, motor examination, where lower scores indicate better motor function. ⁴A 14-item clinical test of balance function (maximum score = 28), where higher scores indicate better balance function. ⁵Cognitive screening-test scoring from 0 to 30, where higher scores indicate better global cognitive function.